^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epirubicin

    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    2d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC (clinicaltrials.gov)
    P3, N=318, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | N=120 --> 318
    Enrollment open • Enrollment change • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    3d
    A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy (ChiCTR2600117206)
    P=N/A, N=30, Not yet recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Exploratory Study of Transarterial Chemoembolization (TACE) Combined with Eparlitozoviril Antibody and Lenvatinib for Intermediate-to-Advanced Hepatocellular Carcinoma (ChiCTR2600117109)
    P=N/A, N=30, Recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    Lenvima (lenvatinib) • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    3d
    A Multicenter Study of Babao Dan to Reduce Inflammation After Treatment for Early-Stage Bladder Cancer (ChiCTR2500113268)
    P=N/A, N=82, Not yet recruiting, Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    epirubicin
    3d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    3d
    Efficacy and Safety of Epirubicin Plus Anlotinib Versus Epirubicin Plus Ifosfamide as Standard First-Line Regimens in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma: A Randomized, Non-Comparative Study (ChiCTR2500113449)
    P2, N=58, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • ifosfamide • epirubicin
    5d
    Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    7d
    Ewing Sarcoma of the Maxilla: An Uncommon Anatomical Presentation in a Young Patient. (PubMed, Cureus)
    The patient underwent subtotal maxillectomy with intraoperative margin assessment, achieving complete surgical excision with histologically negative margins, followed by adjuvant chemotherapy with epirubicin, cisplatin, and ifosfamide, as well as localized radiotherapy. At 18 months of clinical and radiologic follow-up, there was no evidence of local recurrence, with preserved oral function and satisfactory aesthetic outcomes on clinical evaluation. This report highlights the importance of considering malignant small round cell tumors in rapidly enlarging maxillofacial lesions and emphasizes the role of multidisciplinary management in achieving sustained local disease control while preserving postoperative function.
    Journal
    |
    CD99 (CD99 Molecule)
    |
    cisplatin • ifosfamide • epirubicin
    10d
    Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Henan Cancer Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • epirubicin • vincristine • dacarbazine
    13d
    EIC-SNACC: Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study (clinicaltrials.gov)
    P2, N=100, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    epirubicin